AHA 2019 A new tool, connected to the electronic patient files corrects for statin use (type and dose) to determine untreated LDL-c levels and the Dutch lipid score.

AHA 2019 Analyses of the DAPA-HF trial evaluated the effect of dapagliflozin across the age spectrum and based on symptoms, physical and social limitations and QoL at baseline.

AHA 2019 Prof. Kosiborod describes a substudy of the DAPA-HF trial which examined whether dapagliflozin resulted in improvement of symptoms, physical limitations and QoL compared to placebo in HFrEF.

AHA 2019 The GALILEO trial compared a NOAC-based strategy with an antiplatelet-regime after TAVR to obtain insights in the best strategy. Prof. Verheugt tells us what we can learn from this trial.

AHA 2019 The Treat Stroke to Target (TST) trial randomized patients with ischemic stroke or TIA with evidence of atherosclerosis to one of two LDL-c targets and found a benefit of the lower target.

AHA 2019 The EVAPORATE trial was conducted to obtain insights in the mechanism of benefit with icosapent ethyl. Prof. Nicholls describes the first findings of the study.

AHA 2019 The COLCHICINE-PCI trial investigated whether a single dose of the anti-inflammatory agent colchicine, given prior to PCI, resulted in reduced vascular inflammation and myocardial injury after PCI.

AHA 2019 A rivaroxaban-based strategy in patients after successful TAVR resulted in an increased risk of death, thromboembolic and bleeding events, but reduced markers of subclinical leaflet thrombosis compared to an antiplatelet-based regime.

AHA 2019 The siRNA ARO-APOC3 prevents production of APOC3 through RNA interference. It lowered levels of APOC3, TG and VLDL-c and increased HDL-c, and was well tolerated.

AHA 2019 This analysis of the COACT trial showed that there was no difference in survival at 1 year when comparing immediate with delayed coronary angiography after cardiac arrest in NSTEMI patients.

AHA 2019 TWILIGHT-ACS compared ticagrelor monotherapy with ticagrelor plus aspirin in NSTE-ACS patients who were event-free and adherent after 3 months of DAPT.

AHA 2019 As a discussant of the pooled PARAGON-HF and PARADIGM-HF data, dr. Stevenson critically considers the results to get physiological clues on who should be treated and who may not benefit of ARNI therapy.